GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Securities & Investments

Xeris Biopharma Holdings (FRA:2B30) Securities & Investments


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Securities & Investments?

Securities & Investments only applies to banks.


Xeris Biopharma Holdings (FRA:2B30) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.